Mounjaro spare dose: what happens if you have one left in the pen

What the trial programme tells us about dose consistency (and why it matters here

The SURMOUNT-1 study, published in the New England Journal of Medicine, built its weight-loss findings) average reductions of around 20–21% of body weight at the 15 mg dose over 72 weeks, on participants receiving reliable, consistent weekly doses. Dose consistency is not incidental to those results; it is central to them. When people ask about a spare dose, they are often asking a deeper question: did I actually get my full dose this week, and does it matter if I missed a fraction?

It matters, but the answer is rarely what people fear. The KwikPen's mechanism is designed to account for priming fluid and to deliver a pre-measured volume each time. Residual liquid after the fourth injection is expected and is not a 'missed' dose sitting there unused. The pen's dose counter, not the visible fill level, is the reliable indicator of what has been delivered. The NHS medicines information for tirzepatide explains this at a patient level, and the product's SmPC on the electronic Medicines Compendium gives the precise delivery volumes for anyone who wants the technical detail.

The practical upshot: if the pen counted to four, four doses were delivered. If you are unsure whether a single injection completed properly (the pen felt different, the button stuck, or you are not certain the needle was in place) that is a question for your prescriber, not a reason to attempt an additional injection from the same pen.

Why you cannot simply 'use' a leftover dose from a finished pen

This is one of the questions our prescribers hear most regularly, and the concern behind it is completely understandable. Patients notice that the pen does not appear completely empty and wonder whether disposing of it wastes medicine. There are several reasons why attempting to extract or re-use any remaining fluid is not appropriate.

First, the pen locks after the fourth dose specifically to prevent additional injections. That lock is a safety feature, not a mechanical error. Second, tirzepatide's stability once the pen is in use is time-limited; the Mounjaro SmPC on the eMC specifies the maximum period the pen may be kept after first use, and going beyond that window compromises the medicine's integrity. Third, any residual volume is not a full clinical dose, it includes priming fluid and delivery overfill built into the device design. Injecting it separately would deliver an unknown, sub-therapeutic amount.

Storage routine matters here too. Keeping your pen in the fridge door at 2–8 °C through the four-week course is the right approach; once removed from refrigeration, the in-use storage window from the SmPC applies, and a pen kept at room temperature for longer than that should be discarded even if it has not reached the fourth dose. Your full Mounjaro treatment information and the patient information leaflet both cover this.

What to do if you genuinely think a dose was not delivered correctly

Genuine delivery problems do happen occasionally, a needle that was not attached properly, an injection site that bled immediately afterwards, or a button that did not depress fully. These are different from finding residual liquid in a finished pen, and they deserve a different response.

If you have good reason to believe a weekly dose was not delivered, contact your prescriber before injecting again. Taking two doses close together significantly increases the likelihood of gastrointestinal side effects, and your prescriber can advise whether to wait until your next scheduled dose day or take a different course of action. The guide to how many doses are in each pen explains the pen's structure in more detail, which can help you work out where in the four-week cycle a problem may have occurred.

Missing one dose in a course is not a clinical emergency. If the missed dose is within four days of the scheduled day, the guidance is to take it as soon as possible and then continue on the usual schedule. Beyond four days, skip it and resume the following week. These are general principles from the patient information leaflet; your prescriber's advice takes precedence for your specific circumstances. You can find more detail on titration and the dose schedule on the Mounjaro dose page, including guidance on what to expect at the Mounjaro 5 mg dose when you are starting out.

Pen disposal, cost context, and staying on track

Disposing of a pen that appears to have liquid remaining feels wasteful, particularly given the cost of Mounjaro treatment in the UK private market. That feeling is legitimate. The honest answer is that the residual volume is not a usable dose, and safe disposal (into a sharps container, not a household bin) is the right end point for every pen once the fourth dose has been taken or the pen has locked.

Used pens and needles should go into an approved sharps container. Your local pharmacy or GP surgery can advise on collection points. Never recap and re-use needles between doses from the same pen; a fresh needle for each injection is both safer and more comfortable.

If the cost of treatment is a genuine concern, the most useful thing is a conversation with a prescriber about whether your current dose is still the right one, and whether the titration schedule is working for you. Trying to stretch a pen beyond its four doses is not a saving; it introduces uncertainty about what you actually received. The most effective course is the one delivered consistently and reviewed regularly, and if you want a closer look at how the starting strength works in practice, our overview of the Mounjaro 5mg dose covers what patients typically experience in the early weeks. If you have not yet started treatment and want to understand the process, you are welcome to start your free consultation with our prescribing team.